7th Annual MSK Symposium on Lymphoma - On Demand

Wednesday, May 17, 2023, 8:00 AM - Wednesday, January 31, 2024, 11:00 PM

The 7th Annual MSK Symposium on Lymphoma features updated information on lymphoma biology, diagnosis, and ongoing efforts to translate scientific discoveries into novel treatment strategies for a variety of lymphoma subtypes from world-renowned experts.

This year, the clinical management of the most frequent lymphoma entities are addressed and focused sessions related to new families of drugs being developed in these areas as well as in less common presentations are part of the program. Other highlights of this program include coverage of recent advances in the biology of lymphoma and how these will translate to innovative therapeutic interventions and panel discussions on how to best approach patients’ situations.

This on demand includes 15+ recorded lectures, along with select PDF versions of the speakers' slides, from the live Symposium on May 5-6, 2023. Highlights of this on demand offering include:

• Access to both breakout sessions from the live Symposium: Science in Progress as well as the Nursing Professional Development
• Access to both the breakfast Symposium on Chronic Lymphocytic Leukemia as well as the luncheon session on What's new in Multiple Myeloma
• A plenary lecture from Dr. Louis Staudt on Precision Medicine in Diffuse Large B-cell lymphoma
• Special sessions on Lymphoma Classifications, Interpreting Real Life Data, Late Effects of Therapy, and CAR T cells: Update on Eligibility and Toxicity

View the brochure from the 2023 live Symposium for a complete list of available lectures and presenters.

Target Audience

The target audience for this Symposium includes internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in the diagnosis, treatment, and biomedical research of lymphoma.

1. Describe recent refinements in lymphoma classification
2. Discuss first line treatment options in most frequent lymphoma entities
3. Describe new agents mode of actions, efficacy, side effects
4. Discuss options and recommendations for patients in the relapse refractory setting
5. Provide adequate information to help shared decision with patients regarding their treatment

On Demand Access Fees 

• Physicians (MDs, PhDs, PharmDs, and DOs): $450
• Advanced Practice Providers: $200
• Nurses and Other Healthcare Providers: $150
• Residents and Fellows: $100
• MSK Employees: Complimentary

A discount is available for MSK Alumni and MSK Cancer Alliance members to purchase this on demand. If you are a member of one of these groups, contact [email protected] for details. Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

This MSK CME on demand program is non-refundable

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Recorded/Review Date: May 5-6, 2023; Original Release Date: May 17, 2023; Termination Date: January 31, 2024

MSK Symposium Director 

Gilles Salles, MD, PhD
Chief, Lymphoma Service

 

MSK Planning Committee

Annalisa Benz, BSN, RN, OCN 
Nurse Planner

Ahmet Dogan, MD, PhD
Chief, Hematopathology Service

Kojo Elenitoba-Johnson, MD
Chairman, Department of Pathology 

Steven Horwitz, MD
Attending, Lymphoma Service

Andrew Intlekofer, MD
Assistant Attending, Lymphoma Service

Ariela Noy, MD
Attending, Lymphoma Service

Robert Stuver, MD
Hematology/Oncology Fellow

Hans-Guido Wendel, MD
Member/Professor, Cancer Biology and Genetics Program

Joachim Yahalom, MD, FACR, FASTRO
Attending, External Beam Radiotherapy Service

Andrew D. Zelenetz, MD, PhD 
Medical Director, Quality Informatics
Attending, Lymphoma Service 

 

Invited Faculty 

Ranjana Advani, MD
Saul Rosenberg Professor of Lymphoma
Stanford University
Stanford, CA

Philippe Armand, MD, PHD
Professor of Medicine
Dana-Farber Cancer Institute
Boston, MA

Nancy Bartlett, MD
Koman Professor of Medical Oncology
Washington University School of Medicine
St. Louis, MD

Wendy Beguelin, PhD
Assistant Professor of Pharmacology in Medicine
Weill Cornell Medicine
New York, NY

Michael Dickinson, MBBS
Haematologist and Disease Group Lead: Aggressive Lymphoma 
Peter MacCallum Cancer Centre
Melbourne, Australia 

Alex Herrera, MD
Assoicate Professor/Hematologist-Oncologist
City of Hope
Duarte, CA

Caron Jacobson, MD
Assistant Professor, Medicine, Harvard Medical School
Medical Director, Immune Engineered Cell Therapy Program, Medical Oncology
Dana-Farber Cancer Institute
Boston, MA

Michael Khodadoust, MD, PHD
Assistant Professor 
Stanford University
Stanford, CA

Matthew Maurer, MS, DMSc
Assistant Professor of Biostatistics and Medicine
Mayo Clinic
Rochester, MN

Neha Mehta-Shah, MD, MSCI
Associate Professor
Washington University School of Medicine
St. Louis, MD

Lindsay Morton, PhD
Senior Investigator; 
Director, Radiation Epidemiology Branch; 
Head, Cancer Survivorship Research Unit
National Cancer Institute
Bethesda, MD

Loretta Nastoupil, MD
Associate Professor
MD Anderson Cancer Center
Houston, TX

Louis Staudt, MD, PHD
Director, Center for Cancer Genomics
National Institute of Health
Bethesda, MD

Michael Williams, MD
Byrd S. Leavell Professor of Medicine; Division Chief, Medicine: 
Hematology and Oncology
University of Virginia
Charlottesville, VA

 

MSK Faculty 

Omar Abdel-Wahab, MD
Chair, SKI Molecular Pharmacology Program

Alexander Boardman, MD
Hematology Oncology Fellow

Kevin David, MD
Associate Attending, Lymphoma Service

Paola Ghione, MD
Assistant Attending, Lymphoma Service

Brandon Imber, MD, MA
Assistant Attending, Department of Radiation Oncology

Neha S. Korde, MD
Associate Attending, Myeloma Service

Anita Kumar, MD
Assistant Attending, Lymphoma Service

Megan So-Young Lim, MD, PhD
Attending, Department of Pathology

Jennifer K. Lue, MD
Assistant Attending, Lymphoma Service

Brittany McClain, BSN, RN, OCN
Clinical Nurse

Alison J. Moskowitz, MD
Associate Attending, Lymphoma Service

M. Lia Palomba, MD
Member, Lymphoma and Cellular Therapeutics Services

David Qualls, MD
Hematology Oncology Fellow

Gunjan L. Shah, MD, MS
Assistant Attending, Bone Marrow Transplant and Cellular Therapy Services

Meghan Thompson, MD
Assistant Attending, Leukemia Service

Pallawi Torka, MD
Assistant Attending, Lymphoma Service

Saad Z. Usmani, MD, MBA, FACP
Chief, Myeloma Service

Jenna Wenzel, NP-C
Nurse Practitioner

 

Relevant Financial Relationships

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.